BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Health > article

Celltrion allowed to go ahead with last-stage clinical test of COVID-19 antibody treatment

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : September 17, 2020, 17:43 | Updated : September 17, 2020, 17:43
  • 트위터
  • 페이스북
  • 웨이보

[Courtesy of Celltrion]


SEOUL -- South Korea's public health watchdog approved second and third-stage clinical trials to verify the efficacy and safety of a COVID-19 antibody treatment developed by Celltrion, which has vowed to complete preparations for the mass supply of therapeutic antibodies for emergency domestic use by the end of this year.

The Ministry of Food and Drug Safety allowed Celltrion to carry out a Phase 2 clinical study involving 300 patients and a Phase 3 clinical study involving 720 patients. The ministry's approval came after Celltrion's antibody treatment, CT-P59, showed safety and drug tolerance in the first-stage test involving healthy people in August.

South Korea has unveiled a roadmap for the treatment of COVID-19 to develop plasma treatment by the year's end as well as antibody treatment and vaccines next year. The Korea National Institute of Health, a state research body, has selected Celltrion as a cooperation partner to develop vaccines and medicine. In an evaluation test, Celltrion's antibody treatment was found to be effective in neutralizing the mutated strain of the SARS-CoV-2 coronavirus.

Celltrion will carry out clinical trials in the United States and four other countries.

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .Canada approves Celltrions subcutaneous injection for rheumatoid arthritis indication .
    Canada approves Celltrion's subcutaneous injection for rheum…
  • .Celltrions antibody COVID-19 treatment wins approval from S. Korean state watchdog.
    Celltrion's antibody COVID-19 treatment wins approval from S…
  • . Celltrion revises deal with U.S. client to ship new rapid COVID-19 antigen test kit.
    Celltrion revises deal with U.S. client to ship new rapid C…
  • .Anti-epidemic center considers introducing rapid antigen inspection.
    Anti-epidemic center considers introducing rapid antigen ins…

Real Time Photo News

  • .BTS agency posts record earnings in 2020 on brisk online activities and album sales .

    BTS agency posts record earnings in 2020 on brisk online activities and album sales

  • .[FOCUS] BTS agency leagues with Universal Music to launch new K-pop band in US music scene.

    [FOCUS] BTS agency leagues with Universal Music to launch new K-pop band in US music scene

  • .CJ ENM aims to become major visual content producer thru partnership with Epic Games .

    CJ ENM aims to become major visual content producer thru partnership with Epic Games

  • .​Solo singer Sunmi to come back with new album Tail.

    ​Solo singer Sunmi to come back with new album 'Tail'

  • .Big Hits live-streaming joint venture gains reinforcements from Universal Music, YG.

    Big Hit's live-streaming joint venture gains reinforcements from Universal Music, YG

Latest News

more+

  • Prime Minister Chung stresses importance of 'borderless communication channel' to minimize informati…
  • State hospital succeeds in inserting wireless pacemakers into hearts of bradyarrhythmia patients
  • LG Electronics' joint venture with Canada's Magna awaits approval by shareholders in March
  • Sajo Seafood to launch raw tuna menu delivery service
  • Researchers find new roundworm species near Dokdo
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view